BioAesthetics Surpasses Series A Goal Further Advancing the Nipple-Areolar Complex Graft to Clinical Use

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–BioAesthetics Corporation today announced that it has significantly surpassed its Series A funding goal of $2.5 million, further advancing its inaugural product — the nipple-areolar complex (NAC) graft, or NACgraft^TM, for patients who are undergoing breast reconstruction following breast cancer and mastectomy — to clinical use.

BioAesthetics’ Series A was led by a personal commitment from its Director Sandra Coufal, MD, of Sibling Capital Ventures. Dr. Coufal explained, “To mark the 5-year anniversary of my own survival from breast cancer, I felt that support for the development of this product [NACgraft™] and company was a priority investment for me personally in order to…